Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. They are focused on providing new treatment options for cardiometabolic diseases through there complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit…More patients, physicians, and payors.
Gemphire Therapeutics Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.